{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T22:46:14Z","timestamp":1778193974201,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00380-024-02459-6","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T13:01:34Z","timestamp":1728133294000},"page":"227-234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Global use of angiotensin receptor neprilysin inhibitor in heart failure and reduced, below normal and supranormal ejection fraction"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9053-1099","authenticated-orcid":false,"given":"Yu","family":"Horiuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Asami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Yahagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asahi","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Gonda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Yoshiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Komiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Yuzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiro","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,5]]},"reference":[{"issue":"6","key":"2459_CR1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/ejhf.566","volume":"18","author":"MG Crespo-Leiro","year":"2016","unstructured":"Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, Ferrari R, Piepoli MF, Delgado Jimenez JF, Metra M, Fonseca C, Hradec J, Amir O, Logeart D, Dahlstrom U, Merkely B, Drozdz J, Goncalvesova E, Hassanein M, Chioncel O, Lainscak M, Seferovic PM, Tousoulis D, Kavoliuniene A, Fruhwald F, Fazlibegovic E, Temizhan A, Gatzov P, Erglis A, Laroche C, Mebazaa A, Heart Failure Association of the European Society of C (2016) European society of cardiology heart failure long-term registry (ESC-HF-LT): 1\u00a0year follow-up outcomes and differences across regions. Eur J Heart Fail 18(6):613\u2013625","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"2459_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","volume":"72","author":"SJ Greene","year":"2018","unstructured":"Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, Hill CL, McCague K, Mi X, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez AF, Fonarow GC (2018) Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol 72(4):351\u2013366","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2459_CR3","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Investigators P-H, Committees, (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993\u20131004","journal-title":"N Engl J Med"},{"issue":"17","key":"2459_CR4","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Dungen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP, Investigators P-H, Committees, (2019) Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381(17):1609\u20131620","journal-title":"N Engl J Med"},{"issue":"5","key":"2459_CR5","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","volume":"141","author":"SD Solomon","year":"2020","unstructured":"Solomon SD, Vaduganathan M, B LC, Packer M, Zile M, Swedberg K, Rouleau J, M AP, Desai A, Lund LH, Kober L, Anand I, Sweitzer N, Linssen G, Merkely B, Luis Arango J, Vinereanu D, Chen CH, Senni M, Sibulo A, Boytsov S, Shi V, Rizkala A, Lefkowitz M, McMurray JJV, (2020) Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure. Circulation 141(5):352\u2013361","journal-title":"Circulation"},{"issue":"18","key":"2459_CR6","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines. Circulation 145(18):e895\u2013e1032","journal-title":"Circulation"},{"issue":"8","key":"2459_CR7","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1007\/s00380-023-02253-w","volume":"38","author":"N Setoguchi","year":"2023","unstructured":"Setoguchi N, Horiuchi Y, Kawakami T, Nakase M, Watanabe Y, Ishizawa T, Sekiguchi M, Nakajima M, Nonaka H, Asami M, Yahagi K, Komiyama K, Yuzawa H, Tanaka J, Aoki J, Tanabe K (2023) Diuretic and renal effects of angiotensin receptor-neprilysin inhibitor in patients hospitalized for acute heart failure. Heart Vessels 38(8):1042\u20131048","journal-title":"Heart Vessels"},{"issue":"6","key":"2459_CR8","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00380-022-02230-9","volume":"38","author":"A Shirakabe","year":"2023","unstructured":"Shirakabe A, Matsushita M, Sawatani T, Noma S, Takayasu T, Kanai H, Asano M, Nomura A, Asai K (2023) Effect of sacubitril\/valsartan on natriuretic peptide in patients with compensated heart failure. Heart Vessels 38(6):773\u2013784","journal-title":"Heart Vessels"},{"issue":"1","key":"2459_CR9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12872-023-03374-w","volume":"23","author":"X Wang","year":"2023","unstructured":"Wang X, Pu J, Wang G, Xu H, Liu L, Li Z, Qin R, Zhao X, Li M, Hao Z, Hu H (2023) Efficacy and safety analysis of angiotensin receptor neprilysin inhibition(ARNI)in patients with heart failure: a real-world retrospective study. BMC Cardiovasc Disord 23(1):343","journal-title":"BMC Cardiovasc Disord"},{"issue":"23","key":"2459_CR10","doi-asserted-by":"publisher","first-page":"e021970","DOI":"10.1161\/JAHA.121.021970","volume":"10","author":"BJR Buckley","year":"2021","unstructured":"Buckley BJR, Harrison SL, Gupta D, Fazio-Eynullayeva E, Underhill P, Lip GYH (2021) Atrial fibrillation in patients with cardiomyopathy: prevalence and clinical outcomes from real-world data. J Am Heart Assoc 10(23):e021970","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"2459_CR11","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.cardfail.2022.05.001","volume":"28","author":"SJ Greene","year":"2022","unstructured":"Greene SJ, Lautsch D, Yang L, Tan XI, Brady JE (2022) Prognostic interplay between COVID-19 and heart failure with reduced ejection fraction. J Card Fail 28(8):1287\u20131297","journal-title":"J Card Fail"},{"issue":"2","key":"2459_CR12","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1016\/S2665-9913(20)30422-7","volume":"3","author":"A Jorge","year":"2021","unstructured":"Jorge A, D\u2019Silva KM, Cohen A, Wallace ZS, McCormick N, Zhang Y, Choi HK (2021) Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study. Lancet Rheumatol 3(2):e131\u2013e137","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"2459_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","volume":"82","author":"RJ Mentz","year":"2023","unstructured":"Mentz RJ, Ward JH, Hernandez AF, Lepage S, Morrow DA, Sarwat S, Sharma K, Starling RC, Velazquez EJ, Williamson KM, Desai AS, Zieroth S, Solomon SD, Braunwald E, Investigators P-H (2023) Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure. J Am Coll Cardiol 82(1):1\u201312","journal-title":"J Am Coll Cardiol"},{"issue":"31","key":"2459_CR14","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1093\/eurheartj\/ehad344","volume":"44","author":"M Vaduganathan","year":"2023","unstructured":"Vaduganathan M, Mentz RJ, Claggett BL, Miao ZM, Kulac IJ, Ward JH, Hernandez AF, Morrow DA, Starling RC, Velazquez EJ, Williamson KM, Desai AS, Zieroth S, Lefkowitz M, McMurray JJV, Braunwald E, Solomon SD (2023) Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Eur Heart J 44(31):2982\u20132993","journal-title":"Eur Heart J"},{"issue":"5","key":"2459_CR15","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","volume":"43","author":"J Butler","year":"2022","unstructured":"Butler J, Packer M, Filippatos G, Ferreira JP, Zeller C, Schnee J, Brueckmann M, Pocock SJ, Zannad F, Anker SD (2022) Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J 43(5):416\u2013426","journal-title":"Eur Heart J"},{"issue":"1","key":"2459_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","volume":"39","author":"JGF Cleland","year":"2018","unstructured":"Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, Manzano L, McMurray JJV, Ruschitzka F, van Veldhuisen DJ, von Lueder TG, Bohm M, Andersson B, Kjekshus J, Packer M, Rigby AS, Rosano G, Wedel H, Hjalmarson A, Wikstrand J, Kotecha D, Beta-blockers in Heart Failure Collaborative G, (2018) Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 39(1):26\u201335","journal-title":"Eur Heart J"},{"issue":"7","key":"2459_CR17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/ejhf.2895","volume":"25","author":"Y Horiuchi","year":"2023","unstructured":"Horiuchi Y, Asami M, Ide T, Yahagi K, Komiyama K, Yuzawa H, Tanaka J, Aoki J, Matsushima S, Tohyama T, Enzan N, Tsutsui H, Tanabe K (2023) Prevalence, characteristics and cardiovascular and non-cardiovascular outcomes in patients with heart failure with supra-normal ejection fraction: Insight from the JROADHF study. Eur J Heart Fail 25(7):989\u2013998","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"2459_CR18","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/ejhf.1149","volume":"20","author":"LH Lund","year":"2018","unstructured":"Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, Swedberg K, Yusuf S, Granger CB, Pfeffer MA, McMurray JJV, Solomon SD (2018) Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 20(8):1230\u20131239","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"2459_CR19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","volume":"37","author":"SD Solomon","year":"2016","unstructured":"Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O\u2019Meara E, Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA, Investigators T (2016) Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37(5):455\u2013462","journal-title":"Eur Heart J"},{"issue":"19","key":"2459_CR20","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/eurheartj\/eht117","volume":"34","author":"BA Borlaug","year":"2013","unstructured":"Borlaug BA (2013) Heart failure with preserved and reduced ejection fraction: different risk profiles for different diseases. Eur Heart J 34(19):1393\u20131395","journal-title":"Eur Heart J"},{"issue":"10","key":"2459_CR21","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jacc.2018.06.050","volume":"72","author":"J Tromp","year":"2018","unstructured":"Tromp J, Westenbrink BD, Ouwerkerk W, van Veldhuisen DJ, Samani NJ, Ponikowski P, Metra M, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Lang CC, Ng LL, Zannad F, Zwinderman AH, Hillege HL, van der Meer P, Voors AA (2018) Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 72(10):1081\u20131090","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2459_CR22","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/ejhf.890","volume":"19","author":"O Chioncel","year":"2017","unstructured":"Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG, Laroche C, Seferovic PM, Anker SD, Ferrari R, Ruschitzka F, Lopez-Fernandez S, Miani D, Filippatos G, Maggioni AP, Investigators ESCHFL-TR (2017) Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC heart failure long-term registry. Eur J Heart Fail 19(10):1242\u20131254","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"2459_CR23","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/ejhf.945","volume":"19","author":"AS Koh","year":"2017","unstructured":"Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, Savarese G, Lam CSP, Lund LH (2017) A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail 19(12):1624\u20131634","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"2459_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jacasi.2022.11.013","volume":"3","author":"T Nagata","year":"2023","unstructured":"Nagata T, Ide T, Tohyama T, Kaku H, Enzan N, Matsushima S, Ikeda M, Todaka K, Tsutsui H (2023) Long-term outcomes of heart failure patients with preserved, mildly reduced, and reduced ejection fraction. JACC Asia 3(2):315\u2013316","journal-title":"JACC Asia"},{"issue":"4","key":"2459_CR25","doi-asserted-by":"publisher","first-page":"e004745","DOI":"10.1161\/CIRCHEARTFAILURE.117.004745","volume":"11","author":"O Vardeny","year":"2018","unstructured":"Vardeny O, Claggett B, Kachadourian J, Pearson SM, Desai AS, Packer M, Rouleau J, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD (2018) Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril\/valsartan or enalapril: the paradigm-hf trial (prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin-converting enzyme inhibitor to determine impact on global mortality and morbidity in heart failure). Circ Heart Fail 11(4):e004745","journal-title":"Circ Heart Fail"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-024-02459-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00380-024-02459-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-024-02459-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T18:55:43Z","timestamp":1740250543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00380-024-02459-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,5]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2459"],"URL":"https:\/\/doi.org\/10.1007\/s00380-024-02459-6","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,5]]},"assertion":[{"value":"26 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Horiuchi reports other from Astra-Zeneca Co., Ltd., other from Otsuka Pharmaceutical Co., Ltd., other from Ono Pharmaceutical Co., Ltd., other from Novartis Pharma K.K., other from Bayer Yakuhin, other from Mochida Pharmaceutical Co., Ltd., other from Toa Eiyo Co., Ltd., other from Nippon Boehringer Ingelheim Co., Ltd., other from Eli Lilly Japan, grants from Asahi Intecc, outside the submitted work;. Dr. Asami reports other from Takeda Pharmaceutical Co., Ltd., other from Astra-Zeneca Co., Ltd., other from Pfizer Japan Inc., other from Bristol-Myers Squibb Company, other from Otsuka Pharmaceutical Co., Ltd., other from Daiichi Sankyo Co., Ltd., other from Nippon Boehringer Ingelheim Co., Ltd., outside the submitted work;. Dr. Yahagi reports other from Ono Pharmaceutical Co., Ltd., other from Daiichi Sankyo Co., Ltd., other from Novartis Pharma K.K., other from Nippon Boehringer Ingelheim Co., Ltd., other from Bristol-Myers Squibb Company, outside the submitted work; Dr. Komiyama reports other from Otsuka Pharmaceutical Co., Ltd., other from Daiichi Sankyo Co., Ltd., other from Novartis Pharma K.K, other from Kowa Pharmaceutical Co. Ltd., outside the submitted work;. Dr. Yuzawa reports other from Daiichi Sankyo Co., Ltd., other from Kowa Pharmaceutical Co. Ltd., outside the submitted work;. Dr. Tanaka reports other from Novartis Pharma K.K., other from Otsuka Pharmaceutical Co., Ltd., other from Nippon Boehringer Ingelheim Co., Ltd., other from Ono Pharmaceutical Co., Ltd., outside the submitted work;. Dr. Aoki reports other from Novartis Pharma K.K., other from Ono Pharmaceutical Co., Ltd., other from Otsuka Pharmaceutical Co., Ltd., other from Takeda Pharmaceutical Co., Ltd., other from Novartis Pharma K.K, other from Kowa Pharmaceutical Co. Ltd., other from Daiichi Sankyo Co., Ltd., other from Sanofi K.K., other from Amgen Ink., other from Toa Eiyo Co., Ltd., outside the submitted work;. Dr. Tanabe reports other from Astra-Zeneca Co., Ltd., other from Otsuka Pharmaceutical Co., Ltd, other from Ono Pharmaceutical Co., Ltd.,, other from Kowa Pharmaceutical Co. Ltd.,, other from Daiichi Sankyo Co., Ltd.,, other from Takeda Pharmaceutical Co., Ltd.,, other from Toa Eiyo Co., Ltd.,, other from Novartis Pharma K.K, other from Bayer Yakuhin, other from Nippon Boehringer Ingelheim Co., Ltd, other from Eli Lilly Japan, other from Sanofi K.K.,, other from Mitsubishi Tanabe Pharma Corporation, other from Astellas Amgen Bio Pharma, other from Pfizer Japan Inc,, other from Bristol-Myers Squibb Company., outside the submitted work;. The other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}